Cell immunotherapy for the treatment of cancer
AssigneeBoard of Regents, The University of Texas System
InventorsKaty Rezvani, Mayra Shanley, David Marin Costa, Hila Shaim, Elizabeth Shpall
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure encompass compositions comprising immune effector cells, such as natural killer (NK) cells, where the cells comprise one or more exogenously provided interleukins (IL), and wherein the cell optionally comprises one or more engineered receptors. In specific embodiments, the IL is not IL-15, and is IL-12, IL-21, or both. The NK cells may be utilized for treatment of cancer of any kind, including at least glioblastoma.
Claims6
A composition comprising engineered natural killer (NK) cells, said engineered NK cells expressing one or more secretable heterologous interleukins (IL), wherein the secretable heterologous IL is selected from the group consisting of IL-21, IL-12, IL-2, IL-18, IL-7, and the p35 and p40 subunits of IL-12 artificially linked together with a linker, and wherein the NK cell expresses one or more chimeric antigen receptors (CAR) and/or T cell receptors (TCR) that target B7-H3, EGFRvIII, GD2, IL-13Ra2, CD5, CD70, or PRAME.
Dependencies are inferred from the claim text.